Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Marpai, Inc.MRAI · Entity 7110 | See Remarks | January 04, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Marpai, Inc.
Report date January 04, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2033-01-04 | Direct | 200,000 |
Reported balance
After 2023-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-04 · Grant · Acquired 200,000 · Balance 200,000 F1: The option vests monthly over a 36-month period, commencing on September 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests monthly over a 36-month period, commencing on September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2023 Filed Jan 5, 2023 21:02 UTC | Marpai, Inc. MRAI · Entity 7110 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-23-001762 · doc4.xml · derivative · entry 1 Bibring Yoram · CIK 0001576822 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2033-01-04 F1 · derivative.exercise_date: The option vests monthly over a 36-month period, commencing on September 1, 2022. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:08 UTC | Marpai, Inc. MRAI · Entity 7110 | GrantStock Option (Right to Buy) · Derivative | 30,615 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071887 · tm2218660-9_4seq1.xml · derivative · entry 2 Bibring Yoram · CIK 0001576822 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,615 Underlying: Class A Common Stock · 30,615 shares Expires 2032-06-14 F2 · derivative.exercise_date: The option was issued in lieu of a cash bonus and is deemed fully vested on the issuance date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:08 UTC | Marpai, Inc. MRAI · Entity 7110 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071887 · tm2218660-9_4seq1.xml · derivative · entry 1 Bibring Yoram · CIK 0001576822 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 45,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option vests monthly over a 17-month period, commencing on May 1, 2024. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 14:57 UTC | Marpai, Inc. MRAI · Entity 7110 | PurchaseClass A Common Stock | 5,000 | $4.33 | $21,650.00 |
DisclosureSEC source: 0001104659-21-150302 · tm2135529-4_4seq1.xml · nonDerivative · entry 1 Bibring Yoram · CIK 0001576822 · Cheif Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.